Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Levine Cancer Institute-Rock Hill — Rock Hill, South Carolina
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
- Saint Francis Cancer Center — Greenville, South Carolina
- Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in South Carolina: - Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) — Charleston, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in South Carolina: - Ralph H Johnson Veterans Hospital — Charleston, South Carolina
- Gibbs Cancer Center and Research Institute Pelham — Greer, South Carolina
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Gibbs Cancer Center — Spartanburg, South Carolina
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in South Carolina: - AUC Urologists, LLC — Myrtle Beach, South Carolina
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
- Grand Strand Medical Center — Myrtle Beach, South Carolina
- Parkway Surgery Center — Myrtle Beach, South Carolina
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in South Carolina: - START Carolinas — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamid…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT07723248
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in South Carolina: - Research Site 123 — Charleston, South Carolina
- Research Site 108 — Greenville, South Carolina
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …
Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 2 Recruiting Federal
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…
Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in South Carolina: - Ralph H. Johnson VA Medical Center, Charleston, SC — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 2 Recruiting Industry
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Sponsor: AstraZeneca
NCT ID: NCT07181161
Sites in South Carolina: - Research Site — Myrtle Beach, South Carolina
Phase 2 Recruiting Federal
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…
Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in South Carolina: - Ralph H. Johnson VA Medical Center, Charleston, SC — Charleston, South Carolina
Phase 2 Recruiting Industry
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…
Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in South Carolina: - START Carolinas — Myrtle Beach, South Carolina
Phase 2 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants …
Sponsor: Hoffmann-La Roche
NCT ID: NCT07287150
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The m…
Sponsor: Cellvax Therapeutics Inc
NCT ID: NCT06636682
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 2 Recruiting Academic/Other
This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tumor immune response in men recently diagnosed with localized…
Sponsor: Medical University of South Carolina
NCT ID: NCT05586360
Sites in South Carolina: - Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
Phase 2 Recruiting Academic/Other
This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two emerging radiat…
Sponsor: Medical University of South Carolina
NCT ID: NCT07325721
Sites in South Carolina: - Medical University of South Carolina Hollings Cancer Center — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinav…
Sponsor: Medical University of South Carolina
NCT ID: NCT05036226
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in South Carolina: - Exelixis Clinical Site #9 — Myrtle Beach, South Carolina
Phase 1 Recruiting Industry
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amen…
Sponsor: Amgen
NCT ID: NCT04221542
Sites in South Carolina: - Prisma Health Upstate — Greenville, South Carolina